MACROGENICS INC — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MacroGenics announced interim Phase 1 data for MGC026, a B7-H3-targeted antibody-drug conjugate, showing a 27% best overall response rate (6/22 patients: 4 confirmed, 2 unconfirmed partial responses) in 22 heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients with median 3 prior lines of therapy. The drug demonstrated a manageable safety profile with 0% treatment discontinuations due to adverse events in the SCCHN cohort, no cases of interstitial lung disease, pneumonitis, or ocular toxicity. The company plans to initiate a front-line SCCHN combination study with pembrolizumab in early 2027.
Why this rating
Meaningful mid-stage clinical validation for lead program; 27% response rate in difficult-to-treat population is clinically encouraging. Plans expansion to earlier-line setting with checkpoint inhibitor. Significant relative to $73.9M market cap—successful SCCHN development could support valuation growth.
Price action (we called it positive)
before filing · preread $2.44 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.